ClinicalTrials.gg
RecruitingNCT070606903D01Updated Oct 9, 2026

Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes

An interventional study of iCBT with human interaction and Psychoeducational videos in Depression Symptoms, Depression - Major Depressive Disorder and Depressive Disorder, sponsored by Francesc Colom, PsyD, PhD. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Francesc Colom, PsyD, PhD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 225 studies in Depression with a site in Spain — 46 open to participants now, 58 under way, 7 of them phase 3. Depression · Spain.

Planned enrollment
99th of 189
120 · median 123
Started
2026
with 13 others
No phase
153 of 225
35 open now
Primary completion
2027-08
later than 40 of 57 live
Registered
196th of 225
by date

Among the 225 studies in Depression with a site in Spain, this one is the 99th largest by planned enrollment of the 189 interventional ones that give a count, is one of 14 that started in 2026, is one of 153 with no phase, reaches primary completion later than 40 of the 57 other live ones, and was the 196th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

46 of the 225 studies in Depression with a site in Spain are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 225 studies in Depression with a site in Spain, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of a specially developed internet-based Cognitive Behavioural Therapy (CBT) programme with human interaction-referred to as the 3D programme-tailored specifically for women experiencing moderate depressive symptoms. We hypothesise that participation in the intervention will lead to greater improvements in depression severity, compared to receiving only brief psychoeducational videos, when used as an add-on to treatment as usual (TAU) in this population.

The 3D programme is a 10-week blended intervention that includes ten weekly online self-guided modules focused on depression and women's health, along with six individual video sessions with a health/clinical psychologist. The modules cover topics such as mood changes across the menstrual cycle, body image, stress, caregiving, and the impact of gender-based experiences on mental health.

To explore how biological factors may influence how participants respond to treatment, the study will collect biological samples. These will be analysed to track hormone and metabolic changes, with the goal of identifying biological markers that might predict who benefits most from the intervention.

Ultimately, the results of this study aim to improve access to effective and personalised mental health care for women by evaluating whether a structured and personalised online CBT programme can provide meaningful benefits.

Read the detailed description

OBJECTIVES Primary objective: To assess the impact of the 3D programme on depressive symptom severity compared to a psychoeducational control condition.

Secondary objectives: To evaluate improvements in overall functioning, quality of life, perceived stress, and menstruation-related distress. Additionally, the study will investigate metabolic signatures associated with treatment response, focusing on tryptophan and steroid hormone pathways.

HYPOTESES Main hypothesis: Participation in the 3D programme will lead to greater improvements in depression severity (measured by HDRS-17) compared to receiving only informational materials when used as an add-on to Treatment As Usual (TAU) in women experiencing moderate depressive episodes.

Secondary hypotheses:

  1. Participation in the 3D programme will improve overall functioning in women with moderate depressive episodes.
  2. Participation in the 3D programme will improve health-related quality of life in women with moderate depressive episodes.
  3. Participants in the 3D programme with higher perceived stress levels will show less improvement in depression severity compared to those with lower stress levels.
  4. Participants in the 3D programme with higher menstruation-related distress will show greater improvement in depression severity than those with lower levels of distress.
  5. Participants in the 3D programme with more gynaecological problems will experience greater improvement in depression severity than those with fewer gynaecological issues.
  6. A metabolic signature related to tryptophan metabolism and steroid hormones will predict the response to the 3D intervention.
  7. Participation in the 3D programme will lead to changes in hormone production and/or balance, with the persistence of these hormonal changes correlating with the long-term effects of the intervention.

SAMPLE SIZE ESTIMATION AND RECRUITMENT The optimal sample size is estimated to be 60 participants per group. This calculation is based on a Cohen's d effect size of 0.2, a 95% confidence interval, a statistical power of 90%, and an anticipated attrition rate of 20%. Sample size estimation was conducted using G* Power 3.1.7 software.

All patients meeting the inclusion and exclusion criteria will be invited to participate in the study by their treating team at the outpatient mental health facilities within Hospital del Mar. Additionally, gynaecologists at Hospital del Mar will be encouraged to refer patients suspected of experiencing depressive symptoms. In such cases, patients will be screened by the study psychologist/psychiatrist to confirm these symptoms. Recruitment will conclude upon reaching the target of 120 participants with complete data.

RANDOMISATION AND BLINDING Participants will be randomised in a 1:1 ratio using the REDCap randomisation module, which will automatically assign participants to either the experimental or control group through simple randomisation with equal allocation.

This study will implement single blinding. Due to the nature of the intervention, participants will be aware of their group assignment (experimental or control) following randomisation. Likewise, therapists delivering the intervention will be aware of the assigned group, as is standard practice in psychological intervention trials. To uphold the integrity of the blinding process, the following measures will be applied:

  1. Personnel responsible for data analysis will remain blinded to group assignments.
  2. Independent raters conducting outcome assessments will be blinded to participant group allocation.
  3. Other stakeholders, including clinicians, statisticians, and the principal investigator, will remain unaware of the randomisation process and group assignments to minimise potential bias.

STUDY DESING Part 1. Randomised controlled trial The study follows a naturalistic treatment approach, ensuring that all participants continue their usual care. The study will be conducted in accordance with the CONSORT guidelines.

PART 2. Metabolic signature of treatment response The metabolic signature of treatment response will be characterised through the analysis of tryptophan and steroid-related pathways. All analyses will be conducted using methods developed and validated by the Applied Metabolomic Research Group at Hospital del Mar Research Institute, ensuring proper sample handling protocols as outlined in previous studies.

Tryptophan Metabolism:

Tryptophan pathway metabolites-including tryptophan, kynurenine, serotonin, 3-hydroxykynurenine, 5-hydroxyindoleacetic acid, and kynurenic acid-will be quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analysis will follow the protocol established by Marcos et al.

Analysis will focus on the kynurenine/tryptophan (K/T) ratio, a marker of indoleamine-2,3-dioxygenase (IDO) activity, which plays a key role in immune regulation and inflammatory responses.

Additionally, serotonin synthesis and its relationship with tryptophan availability will be assessed, alongside the tryptophan/large neutral amino acid (LNAA) ratio, which serves as an indicator of tryptophan's availability for serotonin production. Data will be integrated using network analysis to identify potential associations between these metabolites and treatment response.

Steroid Hormones:

The steroid profile will be analysed to monitor key sex hormones (e.g., estradiol, testosterone, progesterone) and glucocorticoids (e.g., cortisol, 20α-DHE, and 20β-DHE), along with their metabolites. These hormones play a pivotal role in modulating inflammation and metabolic pathways, with altered levels linked to physiological stress responses and treatment outcomes. These measurements will be performed by LC-MS/MS, following the method previously outlined by the research group.

Biological Samples:

Analysis will be conducted using various biological matrices, including blood, saliva, urine, nails, and hair, to provide complementary insights. Saliva, blood, and urine samples will capture acute metabolic changes at the time of the visit, while nails and hair will reflect chronic metabolite production.

ASSESSMENTS Assessments will be carried out at baseline (T0), immediately following the intervention (3 months after baseline, T1), and at a follow-up assessment (6 months after baseline, T2).

The baseline assessment will include:

  • Collection of socio-demographic and clinical data, with self-reported information gathered via a secure, online-based assessment system (REDCap).
  • Collection of biological samples (blood, saliva, urine, nails, and hair), with sample collection times recorded to account for circadian-sensitive metabolites. These samples will be collected exclusively from cisgender women.
  • A gynaecology consultation to assess hormonal and menstrual complications. These will be evaluated using a 5-point Likert scale, ranging from "1 - No complication" to "5 - Severe complication requiring significant gynaecological intervention or further medical examination." Patients who require additional medical evaluations will be referred for appropriate follow-up care.
  • Metabolic analysis, focusing on tryptophan metabolism and steroid hormone regulation, with the goal of identifying biomarkers predictive of therapeutic outcomes.

Clinical data and biological samples will be collected at all time points.

DATA MANAGEMENT All the data will be text-based (.docx) or numeric format (.xlsx). For all published files, a document record and change track will be included (author contact information, status, version, change reason and date, contents" description, title, origin of the data including a description of the measurement and/or experiment setup) in a separate metadata file for each characterization action called METADATA.ODS.

Data will be stored on a secure server at the Hospital del Mar Research Institute, in compliance with EU and Spanish data protection regulations (General Data Protection Regulation, GDPR, of May 25, 2018; and Organic Law 3/2018 of December 5, on the Protection of Personal Data and Guarantee of Digital Rights).

STATISTICAL ANALYSIS

Primary and Secondary Outcomes:

Analyses will follow an intention-to-treat (ITT) approach, including all participants according to their randomized allocation, regardless of adherence to the intervention.group. Linear mixed-effects models (LMMs) will be used to examine changes over time and between groups for the HDRS-17, WHO-DAS 2.0, EQ-5D-5L, PSS, and MEDI-Q scores. These models will include fixed effects for group, time, and their interaction, and a random intercept for participants to account for within-subject correlation over time. Where appropriate, subscale-level analyses and models using change scores will also be conducted for secondary outcomes. To further explore the temporal dynamics of the intervention's effects, post hoc simple effects analyses will be performed to probe significant interactions.

Additional Analyses:

LLMs and multiple linear regression models will be employed to identify predictors of clinical improvement. Additionally, moderator analyses using linear mixed models will assess whether levels of perceived stress (PSS), or menstrual distress (MEDI-Q) influence treatment response as measured by changes in HDRS-17 scores over time.

Exploratory Biomarker Analyses:

Partial Least Squares Regression (PLSR) and multiple regression will be conducted to model associations between metabolite profiles, their changes over time, and changes in depressive symptoms. Variable Importance in Projection (VIP) scores and cross-validation techniques will be applied to evaluate model performance and identify key predictive biomarkers. Additionally, metabolomic evolution will be assessed through exploratory factor analysis, grouping variables into latent factors.

03

Conditions studied

  • Depression Symptoms
  • Depression - Major Depressive Disorder
  • Depressive Disorder

Keywords

  • Women
  • Metabolomics
  • Depression
  • Internet-Based Intervention
  • Personalized Medicine
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women
  • Age between 18 and 45 years (inclusive)
  • Moderate depressive symptoms, defined by a score of 17 to 23 on the 17-item Hamilton Depression Rating Scale (HDRS-17)
  • Fluent in Spanish
  • Access to the internet and the ability to use digital devices (e.g., smartphone, tablet, or computer)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving psychological therapy
  • Participation in any other interventional clinical trial for depression within the past 3 months
  • Pregnant or planning to become pregnant during the study period
  • Cognitive impairment that may interfere with or study participation
  • Presence of psychotic symptoms, active suicidal ideation, or current substance abuse disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Internet-based Cognitive Behavioural Therapy (iCBT) with human interaction+ Treatment as usual (TAU)

    Participants will undertake the 3D programme, a 10-week internet-delivered cognitive behavioural therapy (iCBT) intervention tailored for women.

    Behavioral: iCBT with human interaction

  • Active comparator
    Brief psychoeducational videos + TAU

    Participants will continue to receive their usual treatment for depression from their healthcare team throughout the study. Additionally, over 10 weeks, they will receive biweekly emails containing links to six brief educational video capsules covering depression causes, behavioural activation, hormonal cycle effects, sleep strategies, healthy habits, and relapse prevention.

    Behavioral: Psychoeducational videos

Interventions

  • BehavioraliCBT with human interaction

    The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.

    Also known as: 3D

  • BehavioralPsychoeducational videos

    This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.

06

What researchers measure

Primary outcomes

  1. Depression severity

    Change in depressive symptoms, as measured by the 17-item Hamilton Depression Rating Scale (HDRS-17), validated in Spanish. Score range: 0 to 52; higher scores indicate more severe depression.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline

Secondary outcomes

  1. Overall functioning

    Change in overall functioning, measured using the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0, 36-item version), self-administered and validated in Spanish.The WHO-DAS 2.0 assesses functioning across six domains. Higher scores indicate greater disability. The Spanish version has demonstrated strong psychometric properties across psychiatric populations.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline

  2. Health-related quality of life

    Change in health-related quality of life, assessed using the EQ-5D-5L, a self-reported questionnaire validated in Spanish. The EQ-5D-5L measures five dimensions. Each dimension is rated on a 5-point scale, and responses are combined into a single index score ranging from below 0 (very poor health) to 1 (perfect health). Additionally, a Visual Analogue Scale (VAS) is included, ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

  3. Perceived Stress

    Change in perceived stress, measured using the Perceived Stress Scale (PSS-10), a 10-item self-reported questionnaire validated in Spanish. Each item is rated on a 5-point scale from 0 (never) to 4 (very often). Total scores range from 0 to 40, with higher scores indicating greater levels of perceived stress.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

  4. Menstruation-related distress

    Change in menstruation-related distress, measured using the Menstrual Distress Questionnaire (MEDI-Q), a 25-item self-reported tool assessing symptoms such as pain, discomfort, psychological changes, gastrointestinal issues, and physiological alterations. The MEDI-Q is a novel instrument and does not yet have a validated Spanish version; this study may contribute to its adaptation for Spanish-speaking populations.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

Other outcomes

  1. Tryptophan metabolism biomarkers

    Quantification of tryptophan and related metabolites (kynurenine, serotonin, 3-hydroxykynurenine, 5-hydroxyindoleacetic acid, kynurenic acid) and calculation of metabolic ratios (e.g., kynurenine/tryptophan ratio) using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Higher or altered levels may be associated with treatment response.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

  2. Steroid hormone profile

    Changes in hormone production and balance over time associated with intervention participation. Measurement of sex hormones (estradiol, testosterone, progesterone) and glucocorticoids (cortisol, 20α-DHE, 20β-DHE) and their metabolites using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Hormonal alterations over time will be evaluated as potential markers of treatment effects.

    Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

07

Study locations

1 of 2 sites recruiting
  • Parc de Recerca Biomèdica de Barcelona
    Barcelona, Barcelona 08003, Spain
    Recruiting
  • Hospital del Mar Research Institute
    Barcelona, Catalonia 08003, Spain
    Not yet recruiting
    • Francesc Colom, PhD · Contactfcolom@researchmar.net · +34933 16 04 00
    • Natalia Angarita-Osorio, PhD · Contactnangarita@researchmar.net · +34 933160400
    • Francesc Colom, PhD · Principal investigator
    • Aitana García-Estela, PhD · Sub investigator
    • Natalia Angarita-Osorio, PhD · Sub investigator
    • Óscar Pozo, PhD · Sub investigator
    • Sílvia Agramunt, PhD · Sub investigator
    • Noemi Haro, Associate Degree · Sub investigator
08

References and documents

Publications

  • Vannuccini S, Rossi E, Cassioli E, Cirone D, Castellini G, Ricca V, Petraglia F. Menstrual Distress Questionnaire (MEDI-Q): a new tool to assess menstruation-related distress. Reprod Biomed Online. 2021 Dec;43(6):1107-1116. doi: 10.1016/j.rbmo.2021.08.029. Epub 2021 Oct 26. PubMed 34753680 ↗
  • Remor E. Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS). Span J Psychol. 2006 May;9(1):86-93. doi: 10.1017/s1138741600006004. PubMed 16673626 ↗
  • Vazquez-Barquero JL, Vazquez Bourgon E, Herrera Castanedo S, Saiz J, Uriarte M, Morales F, Gaite L, Herran A, Ustun TB. [Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): initial phase of development and pilot study. Cantabria disability work group]. Actas Esp Psiquiatr. 2000 Mar-Apr;28(2):77-87. Spanish. PubMed 10937388 ↗
  • Hernandez G, Garin O, Pardo Y, Vilagut G, Pont A, Suarez M, Neira M, Rajmil L, Gorostiza I, Ramallo-Farina Y, Cabases J, Alonso J, Ferrer M. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018 Sep;27(9):2337-2348. doi: 10.1007/s11136-018-1877-5. Epub 2018 May 16. PubMed 29767329 ↗
  • Ramos-Brieva JA, Cordero-Villafafila A. A new validation of the Hamilton Rating Scale for Depression. J Psychiatr Res. 1988;22(1):21-8. doi: 10.1016/0022-3956(88)90024-6. PubMed 3397906 ↗
  • Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013 Sep 5;150(2):384-8. doi: 10.1016/j.jad.2013.04.028. Epub 2013 Jun 4. PubMed 23759278 ↗
  • Krieger T, Bur OT, Weber L, Wolf M, Berger T, Watzke B, Munder T. Human contact in internet-based interventions for depression: A pre-registered replication and meta-analysis of randomized trials. Internet Interv. 2023 Mar 31;32:100617. doi: 10.1016/j.invent.2023.100617. eCollection 2023 Apr. PubMed 37273939 ↗
  • Marx W, McGuinness AJ, Rocks T, Ruusunen A, Cleminson J, Walker AJ, Gomes-da-Costa S, Lane M, Sanches M, Diaz AP, Tseng PT, Lin PY, Berk M, Clarke G, O'Neil A, Jacka F, Stubbs B, Carvalho AF, Quevedo J, Soares JC, Fernandes BS. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021 Aug;26(8):4158-4178. doi: 10.1038/s41380-020-00951-9. Epub 2020 Nov 23. PubMed 33230205 ↗
  • Montcusi B, Madrid-Gambin F, Pozo OJ, Marco S, Marin S, Mayol X, Pascual M, Alonso S, Salvans S, Jimenez-Toscano M, Cascante M, Pera M. Circulating metabolic markers after surgery identify patients at risk for severe postoperative complications: a prospective cohort study in colorectal cancer. Int J Surg. 2024 Mar 1;110(3):1493-1501. doi: 10.1097/JS9.0000000000000965. PubMed 38116682 ↗
  • Marcos J, Renau N, Valverde O, Aznar-Lain G, Gracia-Rubio I, Gonzalez-Sepulveda M, Perez-Jurado LA, Ventura R, Segura J, Pozo OJ. Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry. J Chromatogr A. 2016 Feb 19;1434:91-101. doi: 10.1016/j.chroma.2016.01.023. Epub 2016 Jan 14. PubMed 26818237 ↗
  • Marcos J, Renau N, Casals G, Segura J, Ventura R, Pozo OJ. Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. Anal Chim Acta. 2014 Feb 17;812:92-104. doi: 10.1016/j.aca.2013.12.030. Epub 2014 Jan 3. PubMed 24491769 ↗
  • Angarita-Osorio N, Garcia-Estela A, Terraneo LA, Nunez Pazmino N, Haro N, Pozo OJ, Colom F. A Women-Centered Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms (the 3D Program): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2026 Aug 19;15:e99700. doi: 10.2196/99700. PubMed 42617075 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 17 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 11, 2025
StartActual
Mar 2, 2026was Jan 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
1 site added. Hospital del Mar Research Institute is now Not yet recruiting
Show site
  • Parc de Recerca Biomèdica de Barcelona · Barcelona, Spain
Oct 9, 2026
Start date
Jan 2026→Mar 2, 2026 (actual)
Oct 9, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedMild to moderateModerate depressive symptoms, defined by a score of 17 to 23 on the 17-item Hamilton Depression Rating Scale (HDRS-17)
Oct 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42617075 ↗
Oct 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospital del Mar Research Institute · Barcelona, SpainContact n•••@researchmar.net · •••0400→n•••@researchmar.net · •••0400Contact person changed (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42617075 ↗
    1 site added. Hospital del Mar Research Institute is now Not yet recruiting
    Show site
    • Parc de Recerca Biomèdica de Barcelona · Barcelona, Spain
    Start date Jan 2026→Mar 2, 2026 (now actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedMild to moderateModerate depressive symptoms, defined by a score of 17 to 23 on the 17-item Hamilton Depression Rating Scale (HDRS-17)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospital del Mar Research Institute · Barcelona, SpainContact n•••@researchmar.net · •••0400→n•••@researchmar.net · •••0400Contact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07060690
Lead sponsor
Francesc Colom, PsyD, PhD
Collaborators
Instituto de Salud Carlos III, Hospital del Mar
Responsible party
Francesc Colom, PsyD, PhD (Principal Investigator, Hospital del Mar Research Institute (IMIM)) — Sponsor-investigator
First posted
Jul 11, 2025
Start date
Mar 2, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion